Filing Details

Accession Number:
0000899243-20-034339
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-17 20:30:08
Reporting Period:
2020-12-15
Accepted Time:
2020-12-17 20:30:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1703057 Abcellera Biologics Inc. ABCL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1834424 Tryn Stimart C/O Abcellera Biologics Inc.
2215 Yukon Street
Vancouver A1 V5Y 0A1
Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2020-12-15 250 $20.00 250 No 4 P Direct
Common Shares Acquisiton 2020-12-15 250 $20.00 250 No 4 P Indirect By spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Indirect By spouse
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (right to buy) Acquisiton 2020-10-29 850,000 $0.00 850,000 $2.41
Common Shares Stock Option (right to buy) Acquisiton 2020-12-10 190,800 $0.00 190,800 $20.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
850,000 2030-10-29 No 4 A Direct
190,800 2030-12-10 No 4 A Direct
Footnotes
  1. On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.
  2. The exercise price reported above was converted from the Canadian exercise price of CAD $3.08 using an exchange rate of CAD $1.27840 = US $1.00.
  3. 25% of the shares subject to such option vest and become exercisable on October 29, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
  4. 25% of the shares subject to such option vest and become exercisable on December 31, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
  5. This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.